Opdivo (nivolumab) the Immunotherapy Cancer Treatment

http://youtu.be/s6k8b-SWbfE Opdivo (nivolumab) is an FDA approved immunotherapy cancer drug treatment that is showing great promise for treating various types of cancer, including melanoma, lung cancer, kidney cancer and Hodgkin lymphoma. As a disease, cancer escapes the immune system by producing certain proteins that can hide it. As the cancer can cloak itself, the immune system does not detect it. Opdivo is an antibody that binds to the protein called PD-1 on T cells that live in our immune system. T-cells are like a car ignition that gets the immune system off and running, helping it find and kill cancer cells. Visit http://www.oacancer.com/opdivo-immunotherapy-cancer-treatment/ to learn more about this promising new immunotherapy treatment. Opdivo (nivolumab) is developed by Bristol-Myers Squibb. Besides being FDA approved for the treatment of certain cancers like melanoma and lung cancer, Opdivo is also being studied for the treatment of many other types of cancer. These videos are produced by Dr. Stephen Lemon of Oncology Associates to help provide useful cancer information to patients and survivors. Oncology Associates provides a full range of personalized cancer treatment at its two Omaha clinics, as well as at cancer treatment clinics in Blair and Norfolk, Nebraska. The cancer physicians of Oncology Associates include: * Stephen J. Lemon, MD * Irina E. Popa, MD * Laxmi Narayana R. Buddharaju, MD To learn more about OA's approach to personalized treatment, as well as the oncologists and staff, please visit http://www.oacancer.com